Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 8Phase 1 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adult Solid Tumor 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Has results × carotuximab × Clear all
NCT03181308 2020-06-24

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Tracon Pharmaceuticals Inc.

Phase 1 Completed
11 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03780010 2019-10-28

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Tracon Pharmaceuticals Inc.

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01332721 2018-12-05

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Tracon Pharmaceuticals Inc.

Phase 1 Completed
38 enrolled 8 charts
Other solid neoplasm

Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡